Switching to orforglipron after Ozempic or Mounjaro

What orforglipron actually is

Orforglipron — brand name Foundayo, made by Eli Lilly — received FDA approval on April 1, 2026. It is now shipping to retail pharmacies. The drug activates the GLP-1 receptor the same way semaglutide does. The mechanism is not new. What is new is the molecule.

Semaglutide and tirzepatide are peptides. Peptides are destroyed by stomach acid, which is why Ozempic and Mounjaro are injected — and why the oral semaglutide pill requires an empty stomach, a strict 30-minute fasting window, and no more than four ounces of water. Those conditions exist to protect the peptide long enough to be absorbed. Miss them and bioavailability collapses.

Orforglipron is a small molecule. It does not need protecting. Take it with food, take it with a full glass of water, take it in the middle of the night — none of it matters. That distinction sounds administrative but it has real consequences for real people.

The question the ATTAIN-MAINTAIN trial answered

Plenty of people on injectable GLP-1s want off the needle. The question nobody had a clinical answer to: if you stop the injection and start the pill, what happens to the weight you lost? Does it stay? Does it come back?

ATTAIN-MAINTAIN, published in Nature Medicine in May 2026 and presented at the European Congress on Obesity, was the first randomized controlled trial to test this directly. The trial drew from SURMOUNT-5 — a head-to-head comparison of semaglutide and tirzepatide. Participants who had already lost weight on one of those drugs were switched to orforglipron or placebo for 52 weeks, then tracked.

Two cohorts. One drug each. One clean answer.

The switching numbers

The cardiometabolic improvements carried over too — blood pressure, triglycerides, cholesterol, and waist circumference all held in the orforglipron groups. They did not in placebo.

Weight did tick up slightly during the 52-week trial: about 5 kg in the tirzepatide cohort, about 1 kg in the semaglutide cohort. Some regression from peak is expected when switching to a less potent drug. The meaningful comparison is not "zero weight gain" — it is what happened versus placebo, where regain was substantially greater.

Starting from scratch: what ATTAIN-1 found

ATTAIN-MAINTAIN is a switching trial. But what does orforglipron do for someone starting treatment fresh?

ATTAIN-1, published in the New England Journal of Medicine in September 2025, enrolled 3,127 adults with obesity and no diabetes. At the highest dose (36mg), participants lost an average of 12.4% of body weight — about 27.3 lbs — at 72 weeks. More than half (54.6%) lost at least 10% of their body weight. About 36% lost 15% or more.

For context: semaglutide 2.4mg produces roughly 15–17% weight loss. Tirzepatide produces 20–22%. Orforglipron sits below both on raw numbers. But it outperforms oral semaglutide head-to-head in terms of convenience — and for some patients, the gap in potency is less relevant than the willingness to actually take the drug every day.

The practical edge over oral semaglutide

Novo Nordisk's oral semaglutide (the Wegovy pill) launched in January 2026. It works. But the daily routine is unforgiving: empty stomach, four ounces of water maximum, wait 30 minutes before anything else. The absorption window is narrow because semaglutide is a peptide and needs protection from digestion.

Orforglipron has none of these requirements. Food, water, timing — irrelevant. For someone with a chaotic morning routine, inconsistent schedule, or who already takes several medications, this matters. Adherence is the single most important variable in long-term weight management. A drug taken reliably outperforms a more potent drug taken intermittently. For a full head-to-head breakdown of both pills on weight loss and side effects, see the oral semaglutide vs orforglipron comparison.

Cost and access

Foundayo is available now at U.S. retail pharmacies and via LillyDirect. Self-pay starts at $149 per month for the lowest dose — notably lower than brand-name Ozempic or Wegovy, which often run $900–$1,300 without insurance. People with commercial insurance pay as little as $25 per month with Lilly's savings card. Medicare Part D coverage is expected to average around $50 beginning July 2026.

Compounded orforglipron does not exist. Unlike semaglutide and tirzepatide — which entered compounding channels during shortage periods — orforglipron was never on the FDA shortage list. There is no legal gray-market version. What Lilly sells is what you get.

Who the pill is actually for

If you are already on tirzepatide and it is working, switching to orforglipron trades roughly 8–10 percentage points of weight-loss efficacy for the convenience of a pill. That is a meaningful step down. Most people on tirzepatide who are satisfied should stay.

The pill makes more sense for people who: refuse injections or have needle anxiety; travel frequently and cannot manage cold storage; want to transition off an injection after reaching goal weight; or are new to GLP-1 treatment and prefer to start oral. The ATTAIN-MAINTAIN data suggests the transition can be managed well — you keep most of what you built, even if you do not keep all of it.

One more group: people who tried injectable GLP-1s and stopped due to side effects. Oral dosing may produce a different tolerance profile for some patients, though there is no direct head-to-head tolerability comparison yet.